Slide 1: Next-Generation Enzymatic Therapeutics for Non-Surgical Tissue Repair
February 2024 I Nasdaq: MDWD Next-Generation Enzymatic Therapeuticsfor Non-Surgical Tissue Repair ChronEx Phase II Study Data: A Head-to-Head Comparison of EscharEx® vs. SANTYL®
Slide 2: Cautionary Note Regarding Forward-Looking Statements
2 Cautionary Note Regarding Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws, including but not limited to the statements related to the commercial potential of our products
Slide 3: Comparison to Enzymatic Standard of Care
3 Comparison to Enzymatic Standard of Care 1 OW Primary Research 2 Lantis JC and Gordon I., 2017; Wounds 3 Patry et al., 2017 4 Snyder et al., 2023; Wounds 5 SOC in the Phase 2 trial included SANTYL® 6 Based on the data to date 7 SANTYL® PI EscharEx® Investigational drug - Phase 3 in 2H 2024 Mixture
Slide 4: ChronEx – Multicenter, Randomized, Controlled Phase II Study
ChronEx – Multicenter, Randomized, Controlled Phase II Study 4 Inclusion Criteria: Patients with Venous Leg Ulcers, wound size 2-100 cm2, wound age 4 wks to 2 yrs 1 A standardized selection of non-active dressings to be applied according to their approved label or investigator discretion. Compressio
Slide 5: Comparable Baseline Characteristics
5 Comparable Baseline Characteristics Parameter EscharEx (n=46) SANTYL (n=8) Age (years) - Mean (SD) 65.5 (12.2) 59.9 (11.7) Female Gender - n (%) 20 (43.5%) 4 (50.0%) Wound Age (weeks) - Mean (SD) 26.8 (20.5) 29.1 (27.9) Wound Size (cm2) - Mean (SD) 13.3 (20.4) 10.3 (5.7) Non-Viable Tissue (%) - Me
Slide 6: EscharEx Showed Superiority in Incidence of Complete Debridement
6 EscharEx Showed Superiority in Incidence of Complete Debridement Incidence of complete debridement was 63.0% (95% CI=47.5-76.8) for EscharEx vs. 0% for SANTYL; p=0.001 p=0.001
Slide 7: EscharEx Achieved Complete Debridement Significantly Faster
7 EscharEx Achieved Complete Debridement Significantly Faster Estimated median time to achieve complete debridement was 9 days (95% CI=5-15 days) for EscharExvs. not achieved for SANTYL (95% CI=22-Not Applicable); p=0.023 p=0.023
Slide 8: EscharEx Showed Superiority in the Incidence of Wound Bed Prepared
8 EscharEx Showed Superiority in the Incidence of Wound Bed Prepared Incidence of WBP in Daily Period was 50% (95% CI = 34.9-65.1) for EscharEx and 0% for SANTYL; p=0.015 Throughout study, EscharEx achieved 78.3% (95% CI = 63.6-89.1) vs. 37.5% for SANTYL (95% CI=8.5-75.5); p=0.03 p=0.015 Wound Bed P
Slide 9: EscharEx Achieved Significantly Shorter Time to Wound Bed Prepared
9 EscharEx Achieved Significantly Shorter Time to Wound Bed Prepared Estimated median time to achieve WBP was 11 days (95% CI =7-50 days) for EscharEx vs. not achieved for SANTYL (95% CI=22-Not Applicable); p=0.014 p=0.014
Slide 10: Data Suggests EscharEx Advantage in Wound Closure
10 Data Suggests EscharEx Advantage in Wound Closure 32.6% treated with EscharEx achieved complete wound closure vs. 25% treated with SANTYL (NSS). Average time to wound closure was 48.4 days (SD=23.5) on EscharEx vs. 76.0 days (SD=2.8) on SANTYL; p=0.05 NSS p=0.05
Slide 11: Comparable Safety Profile and Patient Reported Pain
11 Comparable Safety Profile and Patient Reported Pain Adverse Event EscharEx (n=46) SANTYL (n=8) Target wound AEs Skin exfoliation, skin maceration, wound infection, cellulitis 20 (43.5%) 3 (37.5%) Applicational pain AEs 1 (2.2%) 1 (12.5%)
Slide 12: Summary of Results
12 Summary of Results Parameter EscharEx (n=46) SANTYL (n=8) p-value Incidence of complete debridement 63% 0% 0.001 Median time for complete debridement 9 days Not achieved 0.023 Incidence of WBP (daily treatment period) 50.0% 0% 0.015 Incidence of WBP (throughout study) 78.3% 37.5% 0.03 Estimated m